Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
Department of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.
Methods Mol Biol. 2022;2407:365-372. doi: 10.1007/978-1-0716-1871-4_24.
Recently the Tat/rev Induced Limiting Dilution Assay, or TILDA, has been proposed as a possible alternative method to quantify the HIV-1 reservoir. TILDA estimates the frequency of latently infected cells by probing, in a limiting dilution format, the presence or inducibility of tat and rev multiply spliced HIV-1 RNA. In doing so, TILDA reduces overestimation of reservoir size compared to HIV-1 DNA measurements because multiply spliced HIV-1 RNA is less likely to be transcribed from dysfunctional genomes with replication defects. TILDA is easy to perform, requires a very low input number of cells and has a fast turnaround time, making it ideal for use in clinical settings. Here we describe the execution of TILDA with particular emphasis on cell preparation and the limiting dilution scheme.
最近,Tat/rev 诱导的限制稀释分析(TILDA)已被提议作为一种可能的替代方法来定量 HIV-1 储存库。TILDA 通过在限制稀释格式中探测 tat 和 rev 多重拼接的 HIV-1 RNA 的存在或诱导性来估计潜伏感染细胞的频率。通过这种方式,与 HIV-1 DNA 测量相比,TILDA 减少了对储存库大小的高估,因为具有复制缺陷的功能失调基因组不太可能从多重拼接的 HIV-1 RNA 转录。TILDA 易于执行,仅需要非常少量的细胞输入,并且周转时间快,非常适合在临床环境中使用。在这里,我们描述了 TILDA 的执行情况,特别强调了细胞准备和限制稀释方案。